Nasdaq

Ultragenyx Pharmaceutical Inc. Reports Statistically Significant Improvements in Cognitive Function for UX111 Treatment in Sanfilippo Syndrome Type A at WORLDSymposium™ 2025

Ultragenyx announced significant cognitive improvements in Sanfilippo syndrome type A patients treated with UX111 gene therapy, presented at WORLDSymposium™ 2025. Ultragenyx Pharmaceutical Inc.
Business Wire

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer’s Disease Following Monthly Dosing with Low-Dose IL-2 ...

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) ...
Seeking Alpha

DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer

DM199 Demonstrated Highly Statistically Significant and Clinically Meaningful Reductions in Systolic and Diastolic Blood Pressure for Combined Cohorts 6-9 DM199 Did Not Cross the Placental Barrier and ...
Seeking Alpha

OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent ...

New York, New York--(Newsfile Corp. - August 7, 2025) - OS Therapies (OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical ...